- Trial phase
- Preclinical (development candidate nominated)
- Time to market
- Years away. PN-477 is preclinical with no IND filed as of November 2026. If development proceeds, Phase 1 initiation would be at least 12-18 months out, and potential approval (if successful) would be 5+ years away.
- Why 4/10
- PN-477 is a preclinical development candidate with no IND filing, clinical trial start, or regulatory decision scheduled. There is no hard dated catalyst in the next ~12 months, so the impact score defaults to 4 and is capped at 5 per the rubric.
PN-477 is a preclinical-stage asset with no IND filing or clinical trial start announced as of November 2026. Watch for IND filing or Phase 1 initiation updates, but the stock's near-term value is driven by commercial execution of ICOTYDE and MIMRYLO, not this early-stage candidate.
Price Chart
Executive Summary
PN-477 is a wholly-owned preclinical development candidate from Protagonist Therapeutics (PTGX), an oral and injectable GLP-1/GIP/glucagon triple receptor agonist peptide for obesity. It was nominated as a development candidate in June 2025 and remains in preclinical stages as of the company's Q3 2026 update (November 5, 2026). Protagonist is now a profitable, royalty-driven biotech with two FDA-approved drugs (ICOTYDE for psoriasis, MIMRYLO/rusfertide for polycythemia vera) and a deep pipeline including PN-881 (Phase 2b oral IL-17 antagonist). PN-477 is a small, early-stage part of the portfolio with no IND filed or clinical data yet, making it a long-duration option on the obesity market rather than a near-term value driver.
How It Works
PN-477 is a peptide drug that simultaneously activates three gut hormone receptors: GLP-1R, GIPR, and GCGR. This triple-action approach is designed to reduce appetite, increase energy expenditure, and improve blood sugar control for weight loss. It is being developed in both a daily pill form (oral) and a shot (subcutaneous), aiming to match the efficacy of leading injectable obesity drugs while offering more convenient dosing options.
Trial Status
PN-477 was selected as a development candidate in June 2025 after demonstrating "optimal absolute and relative activity against all three hormone receptors in preclinical testing," per management. It has not yet entered IND-enabling studies or clinical trials. The company's Q3 2026 corporate update did not highlight any specific PN-477 milestones, suggesting it remains in early preclinical development.
The Two-Sided Case
Upcoming Catalysts
- IND filing (no date announced)
- Phase 1 clinical trial initiation (no date announced)
- Preclinical data presentations at scientific conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protagonist Therapeutics, Inc 8-K PTGX ·Originating report